Short‐term mortality (< 1 year) · people with acute HBV infection
It is very uncertain whether lamivudine changes short‐term mortality (< 1 year) compared with no intervention (very low certainty).
1 finding from 1 review
Progression to chronic HBV infection · people with acute HBV infection
It is very uncertain whether lamivudine changes progression to chronic HBV infection (6 to 12 months) compared with no intervention (very low certainty).
1 finding from 1 review
Progression to fulminant HBV infection · people with acute HBV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (6 to 12 months) · people with acute HBV infection
1 finding from 1 review
Adverse events (proportion) (12 months) · people with acute HBV infection
It is very uncertain whether lamivudine changes adverse events (proportion) (12 months) compared with no intervention (very low certainty).
1 finding from 1 review
Adverse events (number of events) (12 months) · people with acute HBV infection
It is very uncertain whether lamivudine changes adverse events (number of events) (12 months) compared with no intervention (very low certainty).
1 finding from 1 review
Health‐related quality of life (1 week) · people with acute HBV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Virologic failure 2 successive HIV‐1 RNA >= 200copies/ml at 16+ weeks after randomisation · patients with initial treatment of HIV infection in antiretroviral‐naive individuals
Co‐formulated abacavir‐lamivudine‐zidovudine showed no clear difference in virologic failure 2 successive HIV‐1 RNA >= 200copies/ml at 16+… compared with NNRTIs or PIs (moderate certainty).
1 finding from 1 review
Virologic suppression Viral load < 50 copies/ml · patients with initial treatment of HIV infection in antiretroviral‐naive individuals
Co‐formulated abacavir‐lamivudine‐zidovudine showed no clear difference in virologic suppression Viral load < 50 copies/ml compared with NNRTIs or PIs (moderate certainty).
1 finding from 1 review
CD4 cell count · patients with initial treatment of HIV infection in antiretroviral‐naive individuals
1 finding from 1 review
Severe adverse events · patients with initial treatment of HIV infection in antiretroviral‐naive individuals
Co‐formulated abacavir‐lamivudine‐zidovudine showed no clear difference in severe adverse events compared with NNRTIs or PIs (moderate certainty).
1 finding from 1 review
Hypersensitivity · patients with initial treatment of HIV infection in antiretroviral‐naive individuals
Co‐formulated abacavir‐lamivudine‐zidovudine showed no clear difference in hypersensitivity reactions compared with NNRTIs or PIs (moderate certainty).
1 finding from 1 review